Bipolar Disorder Risk and Your Genetics

Bipolar disorder genetic research has produced one of the most extensively studied bodies of GWAS literature in psychiatry. Across 27 publications spanning 2007 to 2021, genome-wide analyses have identified multiple loci at high functional priority — with ANK3, CACNA1C, SCN2A, and ADCY2 among the most consistent candidates. The converging biological signal points to neuronal excitability pathways: voltage-gated sodium channels, L-type calcium channels, ankyrin scaffolding at the axon initial segment, and cyclic AMP second-messenger signaling.^[1-10]

What is Bipolar Disorder Risk?

Bipolar disorder is a mood condition characterized by recurrent episodes of mania or hypomania alternating with episodes of depression. Manic episodes involve elevated or irritable mood, increased energy, reduced need for sleep, and impulsive or risk-taking behavior. Depressive episodes involve low mood, fatigue, disrupted sleep and appetite, and impaired concentration. The condition affects approximately 1–2 percent of the general population and is among the leading causes of disability worldwide due to its episodic and often chronic course.

Bipolar disorder has among the highest heritability of common psychiatric conditions, estimated at approximately 60–85 percent in twin studies. This strong genetic component has motivated extensive genome-wide association research, yielding a large and growing collection of implicated loci across multiple chromosomal regions.

Research base: Robust.

The genetics behind Bipolar Disorder Risk

Genome-wide association studies of bipolar disorder have identified numerous risk loci across the genome, with functional prioritization analyses elevating specific candidate genes at each locus.^[1-10]

ANK3 (L2G score 0.887) encodes ankyrin-G (ankyrin-3), a scaffolding protein critical for organizing the axon initial segment and nodes of Ranvier. Ankyrin-G recruits and stabilizes voltage-gated sodium channels and potassium channels at the axon initial segment — the site where action potentials are initiated. Disruption of ankyrin-G function alters the precise threshold at which neurons fire, making this locus directly relevant to neuronal excitability. ANK3 is among the most replicated BD GWAS signals across independent studies and is backed by 8 independent credible sets in this dataset.^[1-10]

CACNA1C (L2G score 0.797) encodes the Cav1.2 alpha subunit of L-type voltage-gated calcium channels. L-type calcium channels are expressed in neurons where calcium influx through Cav1.2 activates transcription factor cascades involved in synaptic plasticity, neuronal survival, and circadian rhythm regulation. CACNA1C is one of the most extensively replicated BD loci across independent GWAS datasets, and has also appeared in GWAS of schizophrenia and major depression — suggesting a shared liability dimension across mood and psychotic spectrum conditions.^[1-10]

SCN2A (L2G score 0.949) encodes Nav1.2, a voltage-gated sodium channel expressed at high density in excitatory neurons. Nav1.2 plays a central role in action potential propagation in developing and mature neurons. Common variants near SCN2A have been implicated in bipolar disorder; rare, high-penetrance SCN2A variants cause severe neurodevelopmental conditions, illustrating the spectrum of biological consequences that can arise from variation at this locus.^[1-10]

ADCY2 (L2G score 0.909) encodes adenylate cyclase 2, one of the brain's major adenylyl cyclase isoforms. ADCY2 catalyzes the conversion of ATP to cyclic AMP (cAMP), a second messenger that regulates numerous neuronal signaling pathways through protein kinase A. cAMP signaling has historically been implicated in bipolar pharmacology — lithium, the classic BD mood stabilizer, modulates several targets within signaling cascades adjacent to this pathway, including glycogen synthase kinase 3.^[1-10]

LMAN2L (L2G score 0.963, the highest-ranked gene at its locus) encodes a lectin-type cargo receptor involved in ER-to-Golgi trafficking of specific glycoproteins. Its position as the top-ranked candidate at this GWAS locus suggests a genuine functional signal, though the mechanistic link between LMAN2L glycoprotein trafficking function and bipolar disorder biology remains an active research question.

Additional top-ranked candidates include THSD7A (L2G score 0.915), a thrombospondin type 1 domain-containing protein involved in neuronal migration and synaptogenesis; GRIN2A (L2G score 0.789), the GluN2A subunit of NMDA-type glutamate receptors implicated in synaptic plasticity and long-term potentiation; and SHANK2 (L2G score 0.757), a postsynaptic density scaffolding protein whose rare variants cause autism spectrum disorder and whose common variants appear in psychiatric GWAS broadly.

Ion channel biology convergence across multiple independent BD loci. ANK3, CACNA1C, SCN2A, and KCNB1 represent genetically independent GWAS loci for bipolar disorder, each functionally connected to voltage-gated channel regulation or neuronal excitability. This convergence across separate genomic signals in large GWAS datasets provides strong biological coherence for neuronal excitability as a key dimension of BD genetic architecture.^[1-10]

What the research says

The bipolar disorder GWAS literature represented in this analysis spans 27 published studies (2007–2021), including contributions from the Psychiatric Genomics Consortium and predecessor consortium efforts that pooled samples to achieve the statistical power needed for reliable GWAS discovery.^[1-10] This body of evidence has established bipolar disorder as a highly polygenic condition in which hundreds of loci each contribute small amounts to population-level risk, with no single variant approaching the effect sizes seen in monogenic conditions.

The gene magnitude ranking for this trait reflects 138 L2G-ranked candidate genes across 92 credible sets with functional prioritization data — one of the most densely characterized psychiatric GWAS profiles in the ExomeDNA dataset. The concentration of high-confidence candidates in ion channel and synaptic scaffold gene categories is a consistent finding across independent BD GWAS replication studies.

CACNA1C and ANK3: among the most replicated loci in psychiatric genetics. Both CACNA1C and ANK3 have appeared across multiple independent GWAS of bipolar disorder published since 2007, with the associations strengthening as sample sizes have grown. Their consistent appearance across independent datasets and multiple research groups represents some of the strongest human genetic evidence linking L-type calcium channel function and axon initial segment organization to mood disorder biology.^[1-10]

How Bipolar Disorder Risk affects you

Genetic loading associated with bipolar disorder loci reflects population-level statistical patterns from case-control GWAS. Higher polygenic scores for BD are associated with elevated population-level probability of the condition at the group level — they do not determine whether any individual will experience bipolar disorder, nor do they predict the clinical course, severity, or presentation for anyone who does.

Bipolar disorder is clinically evaluated through comprehensive psychiatric assessment that considers symptom history, episode patterns, family history, and functional impact. Genetic information provides one biological perspective — it should be considered alongside, not in place of, clinical evaluation. Anyone with concerns about mood episodes, sleep patterns, or psychological wellbeing should consult a licensed mental health professional or psychiatrist.

Working with your Bipolar Disorder Risk

The biological pathways implicated in BD GWAS point to several lifestyle domains relevant to neuronal excitability and mood regulation. Sleep regulation and circadian biology intersect directly with L-type calcium channel signaling (CACNA1C) and adenylate cyclase pathways (ADCY2) — both implicated loci have roles in circadian-driven gene expression. Sleep quality is among the lifestyle factors with the most robust evidence for mood stability support in bipolar disorder research broadly.

Physical activity has established associations with hippocampal neuroplasticity, BDNF signaling, and regulation of the HPA axis — a stress-response pathway relevant to mood episode triggering. Omega-3 fatty acid status has appeared in some BD research contexts alongside FADS1 and FADS2 (both L2G-ranked candidates in this dataset), given the role of polyunsaturated fatty acid metabolism in neuronal membrane composition and inflammation biology.

Pharmacological management of bipolar disorder typically requires partnership with a licensed psychiatrist; genetic information about GWAS-level risk variants is not currently used clinically to guide BD medication selection.

Related traits and genes

CACNA1C variants also appear in GWAS of schizophrenia, major depression, and cardiac arrhythmias — reflecting Cav1.2's expression in both neuronal and cardiac tissue. ANK3 appears in cardiac arrhythmia genetics as well, given ankyrin-G's role in organizing Nav channels at cardiac intercalated discs.

GRIN2A encodes a glutamate receptor subunit with entries across multiple neurological and psychiatric GWAS datasets. SHANK2 connects the BD locus landscape to autism genetics research. ADCY2 connects to cAMP signaling biology, which also appears in stress-response and anxiety trait categories.

Related ExomeDNA traits include: Schizophrenia Risk, Major Depression Risk, and additional traits in the Brain & Mental Health category under Mood & Anxiety.

Frequently asked questions

What makes bipolar disorder genetics different from single-gene conditions?

Bipolar disorder is highly polygenic — hundreds to thousands of common genetic variants each contribute a small amount to population-level risk, rather than one or a few variants with large effects. This polygenic architecture means that GWAS findings reflect statistical patterns across large groups, not individual predictions. Rare variants at genes like ANK3 or CACNA1C typically cause more severe neurodevelopmental conditions, while common variants at these loci carry more modest population-level associations with BD specifically.

Why do ANK3 and CACNA1C keep appearing in psychiatric genetics research?

ANK3 and CACNA1C encode proteins central to neuronal excitability — ankyrin-G organizes the axon initial segment where action potentials are initiated, and Cav1.2 calcium channels regulate activity-dependent gene expression. Both are expressed throughout brain circuits relevant to mood regulation. Their consistent appearance across independently conducted GWAS of bipolar disorder, and in some analyses of schizophrenia, suggests these are genuine biological convergence points in the genetic architecture of major psychiatric conditions.

What is the relationship between ADCY2 and bipolar disorder pharmacology?

ADCY2 encodes adenylate cyclase 2, which produces cyclic AMP — a key second messenger in the cAMP/PKA signaling cascade. Lithium, the oldest and most established BD treatment, modulates multiple nodes within related signaling pathways, including glycogen synthase kinase 3 and inositol phosphate metabolism. The convergence of a GWAS signal at ADCY2 with lithium's pharmacological targets in the same signaling neighborhood has been noted in the BD genetics literature, though the connection remains incompletely understood.

Is bipolar disorder genetic risk useful to know about?

Bipolar disorder genetic profiles are most useful as educational information about population-level biology. The data situates an individual's variation within the landscape of GWAS findings without predicting whether the condition will occur. For individuals with a personal or family history of mood episodes, the appropriate step is to consult a licensed mental health professional or psychiatrist — they can provide clinical assessment and guidance appropriate to the individual's situation.

Can BD genetic risk profiles guide treatment decisions?

At present, common-variant GWAS profiles for bipolar disorder are not clinically validated for treatment selection. Pharmacogenomic testing relevant to BD typically focuses on drug metabolism genes (CYP450 enzymes) rather than GWAS risk loci. The loci identified in BD GWAS — including ANK3, CACNA1C, and SCN2A — provide biological insight that may eventually inform therapeutic targeting, but are not currently used in clinical treatment planning. A psychiatrist or clinical pharmacologist can advise on pharmacogenomics approaches that are clinically validated.